By Reed R. Kathrein

The Cost of Make-Believe

There is a fundamental rule in public biotechnology markets: you are legally permitted to run an expensive clinical trial that fails to prove your drug works. Biology is messy, cardiac metrics in rare disease trials are notoriously uncooperative, and drug development is largely an organized way of turning capital into negative data. What you are not permitted to do under the federal securities laws is take that negative data, rewrite the grading rubric twenty-four hours before unblinding the results, tell the public you have achieved pristine, Type I error-controlled statistical significance, and hope the Food and Drug Administration never opens the envelope.

Enter Capricor Therapeutics (NASDAQ: CAPR).

Capricor has spent years developing Deramiocel for Duchenne muscular dystrophy cardiomyopathy. After an initial Complete Response Letter from the FDA in mid-2025 demanding "substantial evidence of effectiveness," Capricor spent early 2026 assuring public investors that its Phase 3 HOPE-3 data was a triumphant success. The endpoints, management told webinars and conferences, were all statistically significant. Commercial manufacturing was spooling up. A PDUFA action date was set. The market sent the stock north of $35.

The Mechanics of the Mirage

In clinical trials, the defense against wishful thinking is the Statistical Analysis Plan (SAP). Before you break the blind and see which patient got the drug and which got saline, you agree on paper—with the FDA—on precisely how you will measure success. You do not get to change the rules of the game after seeing the board.

Except, as alleged in the complaint filed in Nkamga v. Capricor Therapeutics, Inc., No. 3:26-cv-04385 (S.D. Cal.), Capricor did not quite leave the rules alone. According to FDA briefing materials released on July 27, 2026, the trial failed under its original, pre-specified design. So, management generated a brand-new statistical plan—SAP Version 3.0—on November 24, 2025.

Database lock and data unblinding occurred on November 25, 2025. Exactly one day later.

The new arithmetic took the raw clinical changes, converted them into percentage changes, and then converted them back to raw changes—a statistical gymnastics routine the FDA noted was not agreed upon, not scientifically justified, and served primarily to turn a failed trial into a purportedly positive headline. By the time the FDA published its review, it labeled Capricor’s purported wins as post-hoc and exploratory. The stock plunged 64% in a single trading session, falling another 36% when an advisory panel subsequently voted 9–3 against the drug’s efficacy.

The Texts

The beauty of modern regulatory reviews is that when the agency finally issues its briefing documents, it reads like an autopsy performed in plain text. From the FDA's July 2026 briefing documents excerpted in the complaint:

"The study did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months. After completion of the randomized, double blind part of Study HOPE-3 and during Study HOPE-3-OLE (where all patients were treated with deramiocel), changes were made to the pre-specified statistical analysis plan (SAP), generating at least 2 additional versions. Those changes included modifications to the primary and key secondary endpoint definitions; the analytical methods; and the data imputation strategy for certain intercurrent events. FDA noted that the Applicant’s final analyses presented in the BLA submission included additional statistical changes without an associated, updated SAP. The final version of the SAP (v. 3.0), dated November 24, 2025 was not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon. In addition, the process for SAP changes outlined in the study's pre-specified blinding plan was not followed and the final clinical study protocol (Protocol 9.0) deviated from the associated SAP (v. 3.0)[….]  FDA does not consider the conversion of raw change to percent change and then back to raw change to have been scientifically justified, as it adds complexity and reduces accuracy."

There is an enduring corporate mystery in corporate finance: why do issuers assume that the agency reviewing their raw data sets won't notice that the math formula was invented on a Monday afternoon right before opening the trial envelopes on Tuesday morning?

The Enforcement Deficit

The SEC oversees thousands of public filings with an enforcement staff that could fit comfortably inside a mid-sized concert venue. They cannot shadow every biotech sponsor through every interim protocol adjustment. The only structural barrier preventing management from treating clinical statistical models like an open-ended creative writing exercise is FOLS—Fear Of Lawsuit. When management bets the company's valuation on the hope that regulatory reviewers won't check the version history on a PDF, private class actions are the only mechanism left to balance the ledger.

If You Bought the Float

If you happened to purchase $CAPR securities during the period when management claimed the HOPE-3 trial delivered statistically significant primary endpoints under an FDA-aligned protocol, and you are interested in seeing the bill for that discrepancy, our litigation team at Hagens Berman is reviewing the paper trail.

• Case Hub: hbsslaw.com/CAPR
• Email: [email protected]